TLC-ART Program

TLC-ART’s DcNP a Platform Validation

TLC-ART’s innovative technology has now been validated to enable to produce long-acting, targeting multiple drugs simultaneously to HIV-host cells, & to allow a single-dose to carry 3-4 drugs. The following boxes demonstrate platform capabilities and validation.

3-Drug Combo b: LPV/RTV/TFV

  • 3 drugs in 1 nano-dosage
  • One SQ dose last for 2+ wk
  • HIV host cells > plasma drugs
  • Lymph cells > PBMC c

Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.

3-Drug Combo b: ATV/RTV/TFV

  • 3 drugs in 1 nano-dosage
  • One SQ dose last for 2+ wk
  • HIV host cells > plasma drugs
  • Lymph cells > PBMC c

Three HIV Drugs Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.

4-Drug Combo b: LPV/RTV/3TC/TFV

  • 4 drugs in 1 nano-dosage
  • One SQ dose last for 2+ wk
  • HIV host cells > plasma drugs
  • Lymph cells > PBMC c

Long-acting combination anti-HIV drug enhances & sustains higher drug levels in lymph nodes than in blood cells & plasma.

3-Drug Combo b: LPV/EFV/TFV

  • 3 drugs in 1 nano-dosage
  • One SQ dose last for 2+ wk
  • HIV host cells > plasma drugs
  • Lymph cells > PBMC c

Extended cell and plasma drug levels after one dose of a 3-in-1 nanosuspension containing lopinavir, efavirenz, and tenofovir in non-human primates.

a, DcNP; Drug combination Nano-Particle platform developed by the TLC-ART Program

b, LPV, Lopinavir; RTV, Ritonavir; 3TC, Lamivudine; EFV, Efavirenz; TFV, Tenofovir

c, PBMC found in the blood that can be HIV infected

Home